View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jul. 31, 2015	Sep. 09, 2015
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jul. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		33,365,829
Trading Symbol	ADXS
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Condensed Balance Sheets - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Current Assets:
Cash and Cash Equivalents	$ 97,142,340	$ 17,606,860
Prepaid Expenses	366,702	182,978
Income Tax Receivable		1,731,317
Other Current Assets	8,182	8,182
Deferred Expenses - current	1,150,443	964,724
Total Current Assets	98,667,667	20,494,061
Property and Equipment, net	375,688	77,369
Intangible Assets, net	3,142,490	2,767,945
Other Assets	120,863	38,438
TOTAL ASSETS	102,306,708	23,377,813
Current Liabilities:
Accounts Payable	2,153,604	1,411,058
Accrued Expenses	2,293,688	1,241,796
Short Term Convertible Notes and Fair Value of Embedded Derivative	29,549	62,882
Total Current Liabilities	4,476,841	2,715,736
Common Stock Warrant Liability	295,183	32,091
Total Liabilities	4,772,024	2,747,827
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 0 at July 31, 2015 and October 31, 2014. Liquidation preference of $0 at July 31, 2015 and October 31, 2014.
Common Stock - $0.001 par value; authorized 45,000,000 shares, issued and outstanding 31,496,398 at July 31, 2015 and 19,630,139 at October 31, 2014.	31,496	19,630
Additional Paid-In Capital	218,945,481	107,601,493
Accumulated Deficit	(121,442,293)	(86,991,137)
Total Shareholders' Equity	97,534,684	20,629,986
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 102,306,708	$ 23,377,813

Condensed Balance Sheets (Parenthetical) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	31,496,398	19,630,139
Common stock, shares outstanding	31,496,398	19,630,139

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Income Statement [Abstract]
Revenue				$ 1,000,000
Operating Expenses
Research and Development Expenses	7,289,944	3,005,306	17,004,939	6,110,095
General and Administrative Expenses	6,339,335	2,993,739	17,240,302	9,442,630
Total Operating Expenses	13,629,279	5,999,045	34,245,241	15,552,725
Loss from Operations	(13,629,279)	(5,999,045)	(34,245,241)	(14,552,725)
Other Income (expense):
Interest Expense				(5,253)
Gain on Note retirement				6,243
Debt conversion expense			(6,599)
Net changes in fair value of derivative liabilities	32,384	210,298	(254,923)	616,095
Other Income	34,869	9,553	55,608	28,874
Net Loss before benefit for income taxes	(13,562,026)	(5,779,194)	(34,451,155)	(13,906,766)
Income Tax Benefit				625,563
Net Loss	$ (13,562,026)	$ (5,779,194)	$ (34,451,155)	$ (13,281,203)
Net Loss per share, basic and diluted	$ (0.44)	$ (0.30)	$ (1.30)	$ (0.82)
Weighted Average Number of Shares Outstanding, Basic and Diluted	30,955,708	19,273,062	26,400,596	16,294,134

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
OPERATING ACTIVITIES
Net Loss	$ (34,451,155)	$ (13,281,203)
Adjustments to reconcile Net Loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	15,836,492	4,599,259
Non-cash interest expense		51
Loss (Gain) on change in value of warrants and embedded derivative	254,923	(616,095)
Warrant expense	8,169	4,445
Gain on disposal of property and equipment	(10,000)
Settlement expense		34,125
Employee Stock Purchase Plan	18,014	5,371
Depreciation expense	28,352	20,709
Amortization expense of intangibles	151,108	129,434
Debt conversion expense	6,599
(Gain) on note retirement		(6,243)
Change in operating assets and liabilities:
Prepaid expenses	(183,724)	(170,596)
Income tax receivable	1,731,317
Other current assets		(25,000)
Deferred expenses	(185,719)	(566,013)
Security deposit	(82,425)
Accounts payable and accrued expenses	1,794,438	(2,105,153)
Interest payable		(98,192)
Net cash used in operating activities	(15,083,612)	(12,075,101)
INVESTING ACTIVITIES
Purchase of property and equipment	(316,671)	(24,595)
Cost of intangible assets	(525,653)	(288,115)
Net cash used in Investing Activities	(842,324)	(312,710)
FINANCING ACTIVITIES
Repayment of Officer Loan		(64,926)
Proceeds from exercise of options	58,400
Proceeds from exercise of warrants	2,329,708	250
Net proceeds of issuance of Common Stock	94,788,419	14,820,105
Taxes paid related to net share settlement of equity awards	(1,715,111)	(771,028)
Net cash provided by Financing Activities	95,461,416	13,984,401
Net increase in cash and cash equivalents	79,535,480	1,596,590
Cash and cash equivalents at beginning of period	17,606,860	20,552,062
Cash and cash equivalents at end of period	97,142,340	22,148,652
Supplemental Disclosures of Cash Flow Information
Cash Paid for Interest		103,445
Supplemental Schedule of Non-cash Investing and Financing Activities
Accounts Payable from consultants settled with Common Stock		342,309
Conversion of notes payable into common stock	$ 39,932

Organization

9 Months Ended

Jul. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

1. ORGANIZATION

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm -LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm” or “Listeria”), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm -LLO strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Axalimogene filolisbac (ADXS-HPV) is the Company’s lead Lm -LLO immunotherapy product candidate for the treatment of human papilloma virus (“HPV”) associated cancers. The Company completed a randomized Phase 2 study in 110 patients with recurrent cervical cancer that was shown to have a manageable safety profile, apparent improved survival and objective tumor responses. In addition, the Gynecologic Oncology Group (“GOG”), now part of NRG Oncology, is conducting a cooperative group sponsor Phase 2 open-label clinical study of axalimogene filolisbac (ADXS-HPV) in patients with persistent or recurrent cervical cancer with documented disease progression. The study, known as GOG-0265, has successfully completed its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient recruitment which is now enrolling. The Company plans to advance this immunotherapy into a registrational clinical trial for the treatment of women with high-risk locally advanced cervical cancer.

Axalimogene filolisbac (ADXS-HPV) has received United States Food and Drug Administration (“FDA”) orphan drug designation for three HPV-associated cancers: cervical, head and neck, and anal cancer, and is being evaluated in Company-sponsored trials executed under an Investigational New Drug (“IND”) which include the following: i) a Phase 1/2 clinical trial alone and in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in patients with previously treated metastatic HPV-associated cervical cancer and HPV-associated head and neck cancer; ii) a Phase 2 multi-center, open-label study alone and in combination with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360) in patients with Stage I-IIa HPV-associated cervical cancer; iii) a Phase 1/2 study evaluating higher doses and repeat cycles of axalimogene filolisbac (ADXS-HPV) in patients with recurrent cervical cancer; iv) a single arm Phase 2 monotherapy study in patients with metastatic anal cancer and, v) a Phase 2 study in collaboration with and funded by Global BioPharma Inc. (“GBP”), under a development and commercialization license agreement applicable to Asia, of axalimogene filolisbac (ADXS-HPV) in HPV-associated non-small cell lung cancer. In addition to the Company-sponsored trials, axalimogene filolisbac (ADXS-HPV) is also being evaluated in three ongoing investigator-initiated clinical trials as follows: locally advanced cervical cancer (GOG-0265), head and neck cancer (Mount Sinai), and anal cancer (Brown University).

ADXS-PSA is the Company’s Lm -LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (“PSA”) associated with prostate cancer. The Phase 1/2 clinical trial alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, in patients with previously treated metastatic castration-resistant prostate cancer, is currently enrolling patients.

ADXS-HER2 is the Company’s Lm -LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (“HER2”) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers. The FDA has cleared the Company’s IND application and the Company is in the process of initiating a Phase 1b clinical trial in patients with metastatic HER2 expressing solid tumors. The Company received orphan drug designation for ADXS-HER2 in osteosarcoma. Clinical research with ADXS-HER2 in canine osteosarcoma is being developed by the Company’s pet therapeutic partner, Aratana Therapeutics Inc. (“Aratana”), who holds exclusive rights to develop and commercialize ADXS-HER2 and three other Lm -LLO immunotherapies for pet health applications. Aratana has announced that a product license application for use of ADXS-HER2 in the treatment of canine osteosarcoma has been filed with the United States Department of Agriculture (“USDA”). Aratana received communication from the USDA in March 2015 that the efficacy data previously submitted for product license for AT-014 (ADXS-HER2), the cancer immunotherapy for canine osteosarcoma, licensed from the Company was accepted to provide a reasonable expectation of efficacy to support conditional licensure. While Aratana needs to complete additional steps, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2016.

Since inception in 2002, the Company has focused its development efforts on understanding its platform technology and establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, currently those targeting HPV-associated cancer (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2 expressing cancers. Although no immunotherapies have been commercialized to date, research and development and investment continues to be placed behind the advancement of this technology. Pipeline development and the further exploration of the technology for advancement entails risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting and expanding its clinical development program. In addition to its existing single target vectors targeting tumor associated and stromal targets, the Company is actively engaged in the development of new constructs that will address multiple targets that are common to tumor types as well as mutation-associated neo-epitopes. Lastly, the Company is developing certain internal capabilities to manufacture clinical trial materials for its Phase 1 and Phase 2 programs.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock (“Common Stock”). The transaction closed on December 22, 2014, and the Company received net proceeds of approximately $15.8 million from the offering. In addition, on February 18, 2015, the Company priced an additional registered direct offering of 3,068,095 shares of its Common Stock. The transaction closed on February 19, 2015, and the Company received net proceeds of approximately $22.3 million from the offering. The shares in each offering were sold under a Registration Statement (No. 333-194009) on Form S-3, filed by the Company with the United States Securities and Exchange Commission (“SEC”). On May 5, 2015, the Company closed on an underwritten public offering of 2,800,000 shares of Common Stock at a public offering price of $19.00 per share. On May 20, 2015, the Company closed the Underwriters’ overallotment option to purchase 420,000 shares of its Common Stock at a public offering price of $19.00 per share. The net proceeds from the May 2015 public offerings were approximately $56.7 million. On August 25, 2015, the Company priced a registered direct offering of 1,797,269 of its Common Stock at a price of $13.91 per share. The transaction closed on August 28, 2015 and the Company received net proceeds of approximately $25 million. The sale of the shares in these offerings were registered pursuant to a Registration Statement (No. 333- 203497) on Form S-3, filed by the Company with the SEC.

The Company believes its current cash position is sufficient to fund its business plan approximately through fiscal 2018. The estimate is based on assumptions that may prove to be wrong, and the Company could use available capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development and commercialization of its product candidates, the Company is unable to estimate the amount of increased capital outlays and operating expenses associated with completing the development of its current product candidates.

The Company recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan.

Summary of Significant Accounting Policies and Basis of Presentation

9 Months Ended

Jul. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation - Unaudited Interim Financial Information

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and in accordance with the rules and regulations of the SEC with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to represent a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2014 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2014, as filed with the SEC on January 6, 2015.

Revenue Recognition

The Company is expected to derive the majority of its revenue from patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability.

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company’s performance obligations under the collaboration agreement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s consolidated statements of operations.

Estimates

The preparation of financial statements in accordance with GAAP involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of July 31, 2015 and October 31, 2014, the Company had approximately $92.2 million and $- in cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $97.0 million is subject to credit risk at July 31, 2015. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of July 31,
	2015		2014
Warrants		3,263,008		4,587,540
Stock Options		1,933,154		490,338
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,197,738		5,081,232

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.

Recent Accounting Pronouncements

In January 2015, the FASB issued ASU 2015-01, Income Statement —Extraordinary and Unusual Items. The objective of this Update is to simplify the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2014-220—Income Statement—Extraordinary Items (Subtopic 225-20), which has been deleted. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. This Update is not expected to have a material impact on the Company’s condensed financial statements.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

9 Months Ended

Jul. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	July 31, 2015			October 31, 2014
	(Unaudited)
Leasehold Improvements	$	25,685		$	-
Laboratory Equipment		320,927			250,456
Furniture and Fixtures		138,415			72,554
Computer Equipment		2,977			10,717
Total Property and Equipment		488,004			333,727
Accumulated Depreciation and Amortization		(112,316	)		(256,358	)
Net Property and Equipment	$	375,688		$	77,369

Depreciation expense for the three and nine months ended July 31, 2015 and 2014 was $14,204, $28,352, $6,903 and $20,709, respectively.

Intangible Assets

9 Months Ended

Jul. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Pursuant to our license agreement with the University of Pennsylvania, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	July 31, 2015			October 31, 2014
	(Unaudited)
License	$	651,992		$	651,992
Patents		3,637,277			3,111,624
Total intangibles		4,289,269			3,763,616
Accumulated Amortization		(1,146,779	)		(995,671	)
Intangible Assets	$	3,142,490		$	2,767,945

The expirations of the existing patents range from 2015 to 2028 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three and nine months ended July 31, 2015 or 2014. Amortization expense for licensed technology and capitalized patent costs is included in general and administrative expenses and aggregated $52,416, $151,108, $44,818 and $129,434 for the three and nine months ended July 31, 2015 and 2014, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2015 (Remaining)	$	53,500
2016		214,000
2017		214,000
2018		214,000
2019		214,000

Accrued Expenses

9 Months Ended

Jul. 31, 2015

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	July 31, 2015		October 31, 2014
	(Unaudited)
Salaries and Other Compensation	$	999,223	$	890,069
Vendors		35,014		121,200
Legal		537,500		-
Professional Fees		115,862		208,000
Withholding Taxes Payable		606,089		22,527
	$	2,293,688	$	1,241,796

Short-Term Convertible Notes & Fair Value of Embedded Derivative

9 Months Ended

Jul. 31, 2015

Debt Disclosure [Abstract]

Short-Term Convertible Notes & Fair Value of Embedded Derivative

6. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

As of July 31, 2015 and October 31, 2014, the Company had approximately $30,000 and $63,000 in principal outstanding on its junior subordinated convertible promissory notes that are currently overdue and are recorded as current liabilities on the Company’s balance sheet at July 31, 2015 and October 31, 2014, respectively.

During February 2015, the Company induced certain noteholders to convert their convertible promissory notes into common shares by offering conversion prices at a $1.61 discount from the market price of the common stock. In total, $33,333 of promissory notes were converted into 4,104 shares of common stock. In connection with the note conversions, the Company recorded a debt conversion expense of $6,599 in the accompanying statement of operations.

Derivative Instruments

9 Months Ended

Jul. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

7. DERIVATIVE INSTRUMENTS

Warrants

A summary of changes in warrants for the nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	Warrants			Exercise Price
Outstanding Warrants at October 31, 2014:		4,158,092		$	5.42
Issued		2,361		$	7.20
Exercised *		(758,032	)	$	5.10
Expired		(139,413	)	$	10.47
Outstanding Warrants at July 31, 2015		3,263,008		$	5.05

* Includes the cashless exercise of 291,322 warrants that resulted in the issuance of 216,261 shares of common stock.

At July 31, 2015, the Company had approximately 3.23 million of its total 3.26 million outstanding warrants classified as equity (equity warrants). At October 31, 2014, the Company had approximately 4.1 million of its total 4.2 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. The equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

Warrant Liability

At July 31, 2015, the Company had approximately 29,000 of its total approximately 3.26 million outstanding warrants classified as liability warrants (liability warrants). As of October 31, 2014, the Company had approximately 123,000 of its total approximately 4.2 million total warrants classified as liabilities (liability warrants). All of these liability warrants at July 31, 2015 and October 31, 2014 were outstanding. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At July 31, 2015, none of the 29,000 liability warrants are subject to weighted-average anti-dilution provisions. At October 31, 2014, approximately 60,000 of the 123,000 liability warrants are subject to weighted-average anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At July 31, 2015 and October 31, 2014, the fair value of the warrant liability was approximately $295,000 and $32,000, respectively. For the three months ended July 31, 2015 and 2014, the Company reported income of approximately $32,000 and $210,000, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2015 and 2014, the Company reported a loss of approximately $255,000 and income of approximately $616,000, respectively, due to changes in the fair value of the warrant liability. In determining the fair value of the warrant liability, at July 31, 2015 and October 31, 2014, the Company used the following inputs in its BSM:

	July 31, 2015			October 31, 2014

Exercise Price	$	5.63-18.75		$	2.76-21.25

Stock Price	$	16.66		$	3.18

Expected term		92-733 days			4-1006 days

Expected Volatility		84.24%-99.38	%		55.41%-129.38	%

Risk Free Interest Rate		.08%-.67	%		.01%-1.62	%

Exercise of Warrants

During the nine months ended July 31, 2015, warrants to purchase 758,032 shares of common stock were exercised, which resulted in cash proceeds of $2,329,708.

Expiration of Warrants

During the nine months ended July 31, 2015, the Company had 62,430 warrants with anti-dilution provisions, and 76,983 warrants with no such anti-dilution provisions, expire unexercised.

Warrants with anti-dilution provisions

Some of the Company’s warrants contained anti-dilution provisions originally set at $25.00 with a term of five years. As of July 31, 2015, all of these warrants had expired. As of October 31, 2014, these warrants had an exercise price of approximately $7.71. If the Company had issued any Common Stock, except for exempt issuances as defined in the warrant agreement, for consideration less than the exercise price then the exercise price and the amount of warrant shares available would have been adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant agreement. For the nine months ended July 31, 2015, this anti-dilution provision required the Company to issue approximately 2,400 additional warrant shares; and the exercise price to be lowered to $7.20.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computed multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $7.20 and $6.00, weighting the possibility of warrants being exercised at $7.20 between 40% and 50% and warrants being exercised at $6.00 between 60% and 50%.

As of July 31, 2015, there were outstanding warrants to purchase 3,263,008 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $18.75 per share.

As of July 31, 2015, the aggregate intrinsic value of outstanding warrants was approximately $37,643,000.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Share Based Compensation

9 Months Ended

Jul. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation

8. SHARE BASED COMPENSATION

2015 Incentive Plan

On March 30, 2015, the Board of Directors adopted, subject to stockholder approval at the Annual Meeting, the Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan became effective on May 27, 2015 when it was approved by the Company’s stockholders at the 2015 Annual Meeting. The 2015 Plan serves as the successor to the Advaxis, Inc. 2011 Omnibus Incentive Plan (the “Prior Plan”). Effective May 27, 2015, all future equity awards will be made from the 2015 Plan, and no additional awards will be granted under the Prior Plan. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of Common Stock that may be issued under the 2015 Plan is 3,600,000 shares, plus a number of additional shares (not to exceed 650,000) underlying awards outstanding as of the effective date of the 2015 Plan under the Prior Plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason.

Employment Agreements

Management voluntarily purchases restricted stock directly from the Company at market price. The respective stock purchases occur on the last trading day of each month. This voluntary election is outlined in each of Daniel J. O’Connor, Chief Executive Officer and President, David J. Mauro, Executive Vice President, Chief Medical Officer, Gregory T. Mayes, Executive Vice President, Chief Operating Officer and Secretary, Robert G. Petit, Executive Vice President, Chief Scientific Officer and Sara M. Bonstein, Senior Vice President, Chief Financial Officer, (each an “Executive”), employment agreements. The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Nine Months Ended July 31, 2015
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	89,064	$	67,494		6,664	$	61,916		6,329
David J. Mauro	$	16,531	$	12,568		1,257	$	9,514		980
Gregory T. Mayes	$	23,477	$	17,427		1,679	$	14,082		1,387
Robert G. Petit	$	25,225	$	19,335		1,942	$	14,499		1,507
Sara M. Bonstein	$	19,734	$	14,665		1,417	$	11,695		1,137

For the three months ended July 31, 2015, the Company recorded stock compensation expense of $60,795 on the statement of operations representing 3,130 shares of its Common Stock (2,346 shares on a net basis after employee payroll taxes). For the nine months ended July 31, 2015, the Company recorded stock compensation expense of $150,883 on the statement of operations representing 14,435 shares of its Common Stock (12,528 shares on a net basis after employee payroll taxes).

From 2013 to present, in addition to the purchases of Common Stock set forth in the above table, Mr. O’Connor has also purchased an additional 146,616 shares of Common Stock out of his personal funds at the then market price for an aggregate consideration of $588,294. These purchases consisted of the conversion of amounts due to Mr. O’Connor under a promissory note given by Mr. O’Connor to the Company in 2012 of approximately $66,500 for 21,091 shares, 2013 base salary which he elected to receive in Common Stock of approximately $182,919 for 34,752 shares, 2013 and 2014 cash bonus voluntarily requested to receive in equity of approximately $206,125 for 57,990 shares, fiscal 2014 voluntary request to purchase stock directly from the Company at market price purchases of $68,750 for 15,950 shares, and purchases of the Company’s Common Stock in the October 2013 and March 2014 public offerings of 13,500 shares for $54,000 and 3,333 shares for $10,000.

The Executives’ employment agreements entitle them to a performance-based year-end cash bonus. Mr. O’Connor, Dr. Mauro and Mr. Mayes voluntarily requested to be paid all of their bonus, required to be paid in cash, in the Company’s Common Stock instead of cash. Ms. Bonstein voluntarily requested to be paid 75% of her cash bonus in the Company’s Common Stock instead of cash. Dr. Petit received 100% of his bonus in cash. The total fair value of these equity purchases was $457,125, or 137,275 shares of the Company’s Common Stock (104,461 on a net basis after employee payroll taxes).

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2014:		791,879		$	3.81
Granted		641,452		$	16.00
Vested		(362,747	)	$	8.60
Cancelled		(3,333	)	$	11.76
Balance at July 31, 2015		1,067,251		$	9.48

As of July 31, 2015, there was approximately $9,055,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.34 years.

As of July 31, 2015, the aggregate intrinsic value of non-vested RSUs was approximately $7,661,000.

Employee Stock Awards

During the three months ended July 31, 2015, 129,154 shares of Common Stock (100,726 shares on a net basis after employee taxes) were issued to executives and employees related to vested incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $2,361,716.

During the nine months ended July 31, 2015, 292,832 shares of Common Stock (211,957 shares on a net basis after employee taxes) were issued to executives and employees related to incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $3,633,886.

Furthermore, non-executive employees were entitled to receive a performance-based year-end cash bonus. Several non-executive employees requested to be paid all or a portion of their cash bonus in the Company’s Common Stock instead of cash. During the nine months ended July 31, 2105, the total fair value of these equity purchases were $67,671, or 20,322 shares of the Company’s Common Stock (14,300 on a net basis after employee payroll taxes).

Director Stock Awards

During the three months ended July 31, 2015, 23,955 shares of Common Stock were issued to the Directors for compensation related to board and committee membership. Total stock compensation expense to the Directors was $264,552.

During the nine months ended July 31, 2015, 239,850 shares of Common Stock (226,423 shares on a net basis after taxes) were issued to the Directors for compensation related to board and committee membership. Total stock compensation expense to the Directors was $967,631.

Stock Options

A summary of changes in the stock option plan for nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2014:		467,968		$	15.51
Granted		1,618,995		$	13.29
Exercised *		(137,667	)	$	12.29
Expired		(16,142	)	$	36.42
Outstanding at July 31, 2015		1,933,154		$	13.70
Vested and Exercisable at July 31, 2015		712,957		$	14.18

* Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three and nine months ended July 31, 2015, was approximately $1,959,000 and $6,824,000, respectively. For the three and nine months ended July 31, 2014, compensation cost related to the Company’s outstanding stock options was approximately $212,000 and $729,000 respectively.

During the nine months ended July 31, 2015, 1,618,995 options were granted with a total grant date fair value of approximately $28,318,000. During the nine months ended July 31, 2014, 36,000 options were granted with a total grant date fair value of approximately $145,000.

During the nine months ended July 31, 2015, options to purchase 137,667 shares of common stock were exercised, which resulted in cash proceeds of $58,400.

As of July 31, 2015, there was approximately $21,714,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.62 years.

In determining the fair value of the stock options granted during the nine months ended July 31, 2015 and 2014, the Company used the following inputs in its BSM:

	Nine Months Ended
	July 31, 2015			July 31, 2014

Expected Term		5-10 years			5 years

Expected Volatility		108.72%-154.54	%		151.38%-171.12	%

Expected Dividends		0	%		0	%

Risk Free Interest Rate		1.41%-2.27	%		1.39-1.72	%

Shares Issued to consultants

During the three months ended July 31, 2015, 75,628 shares of Common Stock valued at $1,390,107 were issued to consultants for services. During the nine months ended July 31, 2015, 319,278 shares of Common Stock valued at $3,768,014 were issued to consultants for services. The common stock share values were based on the dates the shares vested.

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three and nine months ended July 31, 2015 and 2014, respectively:

	Three Months Ended July 31,				Nine Months Ended July 31,
	2015		2014		2015		2014
Research and development	$	2,499,097	$	303,516	$	4,896,922	$	888,457
General and administrative		3,537,359		1,435,521		10,939,570		3,710,802
Total	$	6,036,456	$	1,739,037	$	15,836,492	$	4,599,259

Commitments and Contingencies

9 Months Ended

Jul. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES:

Legal Proceedings

Iliad Research and Trading

On March 24, 2014, Iliad Research and Trading, L.P. (“Iliad”) filed a Complaint against the Company in the Third Judicial District Court of Salt Lake County, Utah. On June 30, 2014, after Iliad had filed an Amended Complaint, the Company removed the action to the United States District Court for the District of Utah. On August 1, 2014, Iliad filed a Second Amended Complaint (the “SAC”). Iliad alleged that the Company granted a participation right to Tonaquint, Inc. (“Tonaquint”) in a securities purchase agreement between Tonaquint and the Company (the “Purchase Agreement”), pursuant to which Tonaquint was entitled to participate in transactions that the Company structured in accordance with Section 3(a)(10) of the Securities Act of 1933, as amended. Iliad further alleged that the Company’s settlement with Ironridge Global IV, Ltd. (“Ironridge”), pursuant to which the Company issued certain shares of its Common Stock to Ironridge in reliance on the Section 3(a)(10) exemption, occurred without adequate notice for Tonaquint to exercise its participation right. In addition, Iliad alleged that it acquired all of Tonaquint’s rights under the Purchase Agreement in April 2013. The SAC purports to assert claims for breach of contract (express and implied), fraud (federal securities, state securities and common law) and conversion.

On November 24, 2014, in response to the Company’s motion to dismiss, the Court dismissed the conversion claim but denied the remainder of the motion. On December 8, 2014, Advaxis filed its answer to the SAC and a counterclaim (the “Counterclaim”), alleging that Iliad – by purporting to have surreptitiously preserved its claim for breach of Tonaquint’s alleged right to participate in the Ironridge transaction – had fraudulently induced Advaxis to enter into the parties’ post-assignment Exchange and Settlement Agreement and, in the alternative, had breached the covenant of good faith and fair dealing implied therein. On January 23, 2015, Iliad filed its Reply to Counterclaim. On May 4, 2015, in response to Iliad’s motion for partial summary judgment concerning liability on the express contract claim and Advaxis’ Rule 56(d) motion to deny that motion and allow discovery, the Court found that Advaxis had materially breached the Purchase Agreement.

On September 10, 2015, the parties entered into a definitive confidential settlement agreement, pursuant to which Iliad will file a stipulation of dismissal shortly, and the Company accrued such amounts.

Knoll

On August 21, 2015, Knoll Capital Management L.P. (“KCM”) filed a complaint against the Company in the Delaware Court of Chancery. The complaint alleges the existence of an oral agreement for the purchase by Knoll from the Company of 1,666,666.67 shares of Company stock at a price of $3.00 per share. KCM alleges that the Company breached this alleged agreement and seeks specific performance or, alternatively, money damages for breach of contract. KCM served the Company with the complaint on August 31, 2015, and the Company has until September 21, 2015 to either answer or move to dismiss the complaint. The Company intends to defend itself vigorously.

Numoda

On June 19, 2009, the Company entered into a master agreement and on July 8, 2009, the Company entered into a Project Agreement with Numoda Corporation (“Numoda”), to oversee Phase 2 clinical activity with axalimogene filolisbac (ADXS-HPV) for the treatment of invasive cervical cancer and CIN.

On October 1, 2014, the Company filed a Complaint against Numoda seeking a declaratory judgment that, with its tender to Numoda of a check for $68,884, the Company had fully performed the parties’ Project Agreement and that Numoda was not entitled to interest, costs or attorneys’ fees thereunder or otherwise. On January 9, 2015, Numoda filed papers in support of its motion to dismiss the Complaint. On January 23, 2015, the Company filed an Amended Complaint against Numoda seeking an order directing Numoda to specifically perform its obligation to deliver to Advaxis all materials, information and other data generated under the parties’ Project Agreement. On February 25, 2015, the Court endorsed a letter from Numoda’s counsel withdrawing its motion to dismiss the Complaint in light of the Amended Complaint. On February 20, 2015, Numoda filed an Answer denying liability and asserting a number of affirmative defenses. With Court approval of a stipulation of the parties, the Preliminary Conference was adjourned from May 28, 2015 until October 29, 2015.

Larkin and Bono

On July 27, 2015, a derivative complaint was filed by a purported Company shareholder in the Court of Chancery of the State of Delaware against certain of the Company’s officers and directors styled Timothy Larkin v. O’Connor, et al., Case No. 11338-VCB (Del. Ch. July 27, 2015). The action was brought derivatively on behalf of the Company, which is also named as a nominal defendant. On August 20, 2015, a related derivative complaint was filed by a purported Company shareholder in the United States District Court for the District of New Jersey against the same defendants styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015). Both complaints are based on general allegations related to certain stock options granted to the individual defendants and generally allege counts for breaches of fiduciary duty and unjust enrichment. The Bono complaint alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. Both complaints seek damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief. At this early stage of each proceeding, the Company does not express any opinion as to the likely outcome, but the Company intends to defend each action vigorously.

The Company is from time to time involved in legal proceedings in the ordinary course of its business. The Company does not believe that any of these claims and proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on its financial condition or results of operations.

Operating Leases

The Company’s corporate offices are currently located at 305 College Road East, Princeton, New Jersey 08540. On April 1, 2011, the Company entered into a sublease agreement for such office, and the agreement has a termination date of November 29, 2015.

In May 2015, the Company signed a direct lease for an expansion area, as well as a direct lease for the existing office, lab and vivarium space upon the expiration of the sublease agreement, which is approximately 20,000 square foot of space in Princeton, NJ. The lease term is seven years and expires on November 30, 2022. The Company paid a security deposit of $82,426. The lease requires base annual rent of approximately $442,000 with annual increases in increments between 2% and 4% throughout the remainder of the lease. Rent expense will be recognized on a straight line basis over the term of the lease. The lease contains two options to renew for five years each.

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2015 (Remaining)	$	60,000
2016		424,927
2017		450,451
2018		468,947
2019		488,153
Thereafter		1,625,308

The Company plans to continue to rent necessary offices and laboratories to support its business.

Shareholders' Equity

9 Months Ended

Jul. 31, 2015

Equity [Abstract]

Shareholders' Equity

10. SHAREHOLDERS’ EQUITY

Registered Direct Offerings

On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock at $4.25 per share. The transaction closed on December 22, 2014, and the Company received gross proceeds of approximately $16.7 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $15.8 million.

On February 18, 2015, the Company priced a registered direct offering of 3,068,095 shares of its Common Stock at $7.50 per share. The transaction closed on February 19, 2015, and the Company received gross proceeds of approximately $23.0 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $22.3 million.

Public Offerings

On May 5, 2015, the Company closed on an underwritten public offering of 2,800,000 shares of Common Stock at a public offering price of $19.00 per share. On May 20, 2015, the Company closed the Underwriters’ overallotment option to purchase 420,000 shares of its Common Stock at a public offering price of $19.00 per share. The Company received gross proceeds of approximately $61.2 million from the May 2015 public offerings. After deducting offering expenses, the net proceeds from the May 2015 public offerings were approximately $56.7 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Fair Value

9 Months Ended

Jul. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value

11. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2015 and October 31, 2014:

July 31, 2015	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $5.63 - $18.75 from May 2015 through August 2017	$	-	$	-	$	295,183	$	295,183

October 31, 2014	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$	-	$	32,091	$	32,091

Common stock warrant liability:

	July 31, 2015
	(Unaudited)
Beginning balance: October 31, 2014	$	32,091
Issuance of additional warrants due to anti-dilution provisions		8,169
Change in fair value		254,923

Balance at July 31, 2015	$	295,183

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Subsequent Events

9 Months Ended

Jul. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

12. SUBSEQUENT EVENTS

On August 10, 2015, the Company issued 58,126 shares of Common Stock valued at $921,297 to an accredited investor as payment for consulting services rendered.

On August 13, 2015, the Board of Directors appointed The Honorable Tom Ridge, the first Secretary of the U.S. Department of Homeland Security and 43^rd Governor of Pennsylvania, to the Board. Governor Ridge will serve as a director until his term expires at the 2016 annual meeting of stockholders, at which time he will stand for election by the Company’s stockholders. In consideration for his services as a director, Governor Ridge received 636 shares of common stock valued at $10,952 and options to purchase 50,000 shares of common stock at an exercise price of $17.22. The options vest on August 13, 2016 and expire in 10 years. Governor Ridge was also granted 15,240 RSUs, with 2,740 RSU’s vesting on October 31, 2015 and the remaining 12,500 RSUs vesting quarterly such that 100% of the RSUs will have vested by October 31, 2016.

On August 17, 2015, the Company issued 1,250 shares of common stock to an employee which represents the initial vesting period of an inducement grant pursuant to his Employment Agreement.

On August 18, 2015, The Company issued 2,379 shares of common stock to employees in connection with the Employee Stock Purchase Plan.

On August 26, 2015, the Company entered into a licensing agreement with Knight Therapeutics Inc. (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, to commercialize in Canada the Company’s product candidates. Under the terms of the licensing agreement, Knight will be responsible to conduct and fund all regulatory and commercial activities in Canada. The Company is eligible to receive royalty and sales milestones as defined in the agreement.

In connection with the licensing agreement, the Company sold directly to Knight 359,454 shares of the common stock at $13.91 per share. In addition, the Company sold directly to Sectoral Asset Management, a leading Canadian-based global healthcare investment advisor, 1,437,815 shares of common stock at $13.91 per share. The combined net proceeds to the Company from these direct investments is approximately $25 million. The sale of the shares closed on August 28, 2015.

On August 31, 2015, the Company issued 1,020 shares of Common Stock to management, pursuant to their Employment Agreements.

On September 8, 2015, the Company issued 8,750 shares of Common Stock to employees which represents the initial vesting period of inducement grants pursuant to their employment agreements.

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

9 Months Ended

Jul. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation - Unaudited Interim Financial Information

Basis of Presentation - Unaudited Interim Financial Information

Revenue Recognition

Revenue Recognition

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

Estimates

Estimates

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Net Loss per Share

Net Loss per Share

	As of July 31,
	2015		2014
Warrants		3,263,008		4,587,540
Stock Options		1,933,154		490,338
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,197,738		5,081,232

Stock Based Compensation

Stock Based Compensation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

9 Months Ended

Jul. 31, 2015

Accounting Policies [Abstract]

Schedule of Common Stock Excluded From Diluted Net Loss Per Share

The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of July 31,
	2015		2014
Warrants		3,263,008		4,587,540
Stock Options		1,933,154		490,338
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,197,738		5,081,232

Property and Equipment (Tables)

9 Months Ended

Jul. 31, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following:

	July 31, 2015			October 31, 2014
	(Unaudited)
Leasehold Improvements	$	25,685		$	-
Laboratory Equipment		320,927			250,456
Furniture and Fixtures		138,415			72,554
Computer Equipment		2,977			10,717
Total Property and Equipment		488,004			333,727
Accumulated Depreciation and Amortization		(112,316	)		(256,358	)
Net Property and Equipment	$	375,688		$	77,369

Intangible Assets (Tables)

9 Months Ended

Jul. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

The following is a summary of intangible assets as of the end of the following fiscal periods:

	July 31, 2015			October 31, 2014
	(Unaudited)
License	$	651,992		$	651,992
Patents		3,637,277			3,111,624
Total intangibles		4,289,269			3,763,616
Accumulated Amortization		(1,146,779	)		(995,671	)
Intangible Assets	$	3,142,490		$	2,767,945

Schedule of Amortization Expense

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2015 (Remaining)	$	53,500
2016		214,000
2017		214,000
2018		214,000
2019		214,000

Accrued Expenses (Tables)

9 Months Ended

Jul. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The following table represents the major components of accrued expenses:

	July 31, 2015		October 31, 2014
	(Unaudited)
Salaries and Other Compensation	$	999,223	$	890,069
Vendors		35,014		121,200
Legal		537,500		-
Professional Fees		115,862		208,000
Withholding Taxes Payable		606,089		22,527
	$	2,293,688	$	1,241,796

Derivative Instruments (Tables)

9 Months Ended

Jul. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Warrants Activity

A summary of changes in warrants for the nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	Warrants			Exercise Price
Outstanding Warrants at October 31, 2014:		4,158,092		$	5.42
Issued		2,361		$	7.20
Exercised *		(758,032	)	$	5.10
Expired		(139,413	)	$	10.47
Outstanding Warrants at July 31, 2015		3,263,008		$	5.05

* Includes the cashless exercise of 291,322 warrants that resulted in the issuance of 216,261 shares of common stock.

Schedule of Fair Value of Warrant Liability

	July 31, 2015			October 31, 2014

Exercise Price	$	5.63-18.75		$	2.76-21.25

Stock Price	$	16.66		$	3.18

Expected term		92-733 days			4-1006 days

Expected Volatility		84.24%-99.38	%		55.41%-129.38	%

Risk Free Interest Rate		.08%-.67	%		.01%-1.62	%

Share Based Compensation (Tables)

9 Months Ended

Jul. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Allocation of Base Salary

The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Nine Months Ended July 31, 2015
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	89,064	$	67,494		6,664	$	61,916		6,329
David J. Mauro	$	16,531	$	12,568		1,257	$	9,514		980
Gregory T. Mayes	$	23,477	$	17,427		1,679	$	14,082		1,387
Robert G. Petit	$	25,225	$	19,335		1,942	$	14,499		1,507
Sara M. Bonstein	$	19,734	$	14,665		1,417	$	11,695		1,137

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2014:		791,879		$	3.81
Granted		641,452		$	16.00
Vested		(362,747	)	$	8.60
Cancelled		(3,333	)	$	11.76
Balance at July 31, 2015		1,067,251		$	9.48

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for nine months ended July 31, 2015 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2014:		467,968		$	15.51
Granted		1,618,995		$	13.29
Exercised *		(137,667	)	$	12.29
Expired		(16,142	)	$	36.42
Outstanding at July 31, 2015		1,933,154		$	13.70
Vested and Exercisable at July 31, 2015		712,957		$	14.18

* Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the nine months ended July 31, 2015 and 2014, the Company used the following inputs in its BSM:

	Nine Months Ended
	July 31, 2015			July 31, 2014

Expected Term		5-10 years			5 years

Expected Volatility		108.72%-154.54	%		151.38%-171.12	%

Expected Dividends		0	%		0	%

Risk Free Interest Rate		1.41%-2.27	%		1.39-1.72	%

Summary of Share-based Compensation Expense

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three and nine months ended July 31, 2015 and 2014, respectively:

	Three Months Ended July 31,				Nine Months Ended July 31,
	2015		2014		2015		2014
Research and development	$	2,499,097	$	303,516	$	4,896,922	$	888,457
General and administrative		3,537,359		1,435,521		10,939,570		3,710,802
Total	$	6,036,456	$	1,739,037	$	15,836,492	$	4,599,259

Commitments and Contingencies (Tables)

9 Months Ended

Jul. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments of Operating Leases

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2015 (Remaining)	$	60,000
2016		424,927
2017		450,451
2018		468,947
2019		488,153
Thereafter		1,625,308

Fair Value (Tables)

9 Months Ended

Jul. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2015 and October 31, 2014:

July 31, 2015	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $5.63 - $18.75 from May 2015 through August 2017	$	-	$	-	$	295,183	$	295,183

October 31, 2014	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$	-	$	32,091	$	32,091

Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation

Common stock warrant liability:

	July 31, 2015
	(Unaudited)
Beginning balance: October 31, 2014	$	32,091
Issuance of additional warrants due to anti-dilution provisions		8,169
Change in fair value		254,923

Balance at July 31, 2015	$	295,183

Organization (Details Narrative)						1 Months Ended	9 Months Ended
Organization (Details Narrative)	Aug. 28, 2015 USD ($)	Aug. 25, 2015 $ / shares shares	Feb. 18, 2015 USD ($) shares	Dec. 22, 2014 USD ($)	Dec. 19, 2014 shares	May 31, 2015 USD ($)	Jul. 31, 2015 ft²	May 20, 2015 $ / shares shares	May 05, 2015 $ / shares shares
Number of patients \| ft²							110
Shares issued during period to direct offering		1,797,269	3,068,095		3,940,801
Proceeds from registered direct offering \| $				$ 15,800,000
Number of shares closed under underwritten public offering									2,800,000
Shares closed under underwritten public offering, per share value \| $ / shares		$ 13.91							$ 19.00
Proceeds from public offering \| $	$ 25,000,000		$ 22,300,000			$ 56,700,000
Over-Allotment Option [Member]
Number of shares closed under underwritten public offering								420,000
Shares closed under underwritten public offering, per share value \| $ / shares								$ 19.00

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Accounting Policies [Abstract]
Concentration of credit risk	$ 97,000,000
Cash equivalents	$ 92,200,000

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Common Stock Excluded From Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Number of common stock excluded from diluted net loss per share	5,197,738	5,081,232
Warrant [Member]
Number of common stock excluded from diluted net loss per share	3,263,008	4,587,540
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	1,933,154	490,338
Convertible Debt [Member]
Number of common stock excluded from diluted net loss per share	1,576	3,354

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 14,204	$ 6,903	$ 28,352	$ 20,709

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Leasehold Improvements	$ 25,685
Laboratory Equipment	320,927	250,456
Furniture and Fixtures	138,415	72,554
Computer Equipment	2,977	10,717
Total Property and Equipment	488,004	333,727
Accumulated Depreciation and Amortization	(112,316)	(256,358)
Net Property and Equipment	$ 375,688	$ 77,369

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Amortization expense of licensed technology and capitalized patent costs	$ 52,416	$ 44,818	$ 151,108	$ 129,434
Minimum [Member]
Finite lived patents expirations			2015
Maximum [Member]
Finite lived patents expirations			2028

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 651,992	$ 651,992
Patents	3,637,277	3,111,624
Total intangibles	4,289,269	3,763,616
Accumulated Amortization	(1,146,779)	(995,671)
Intangible Assets	$ 3,142,490	$ 2,767,945

Intangible Assets - Schedule of Amortization Expense (Details)	Oct. 31, 2014 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (Remaining)	$ 53,500
2016	214,000
2017	214,000
2018	214,000
2019	$ 214,000

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Payables and Accruals [Abstract]
Salaries and Other Compensation	$ 999,223	$ 890,069
Vendors	35,014	121,200
Legal	537,500
Professional Fees	115,862	208,000
Withholding Taxes Payable	606,089	22,527
Accrued Liabilities, Current	$ 2,293,688	$ 1,241,796

Short-Term Convertible Notes & Fair Value of Embedded Derivative (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2015	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014	Oct. 31, 2014
Debt Disclosure [Abstract]
Short-term convertible notes and fair value of embedded derivative		$ 29,549		$ 29,549		$ 62,882
Conversion price of convertible promissory notes	$ 1.61
Value of convertible promissory notes	$ 33,333
Number of shares issued upon conversion	4,104
Debt conversion expense				$ 6,599

Derivative Instruments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Derivative Instruments (Details Narrative) - USD ($)	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014	Oct. 31, 2014	Oct. 01, 2014
Warrants outstanding	3,263,008		3,263,008		4,158,092
Fair value of embedded derivative	$ 295,000		$ 295,000		$ 32,000
Income on embedded derivative liability	$ 32,000	$ 210,000	$ (254,923)	$ 616,095
Warrants to purchase of common stock exercised during period			758,032
Cash proceeds			$ 2,329,708	$ 250
Anti-dilution provision warrant			62,430
Anti-dilution warrants expired			76,983
Anti-dilution provisions warrants exercise price			$ 25.00
Anti-dilution provision warrants period			5 years
Warrants exercise price	$ 7.20		$ 7.20		$ 7.71
Anti-dilution provisions additional warrants issuable			2,400
Exercise price per share	$ 5.05		$ 5.05		5.42
Aggregate intrinsic value of outstanding warrants	$ 37,643,000		$ 37,643,000
Maximum [Member]
Anti-dilution provisions warrants exercise price			$ 7.20
Probability of exercise of additional warrants at exercise price one			40.00%
Probability of exercise of additional warrants at exercise price two			50.00%
Exercise price per share	$ 18.75		$ 18.75		21.25
Maximum [Member] \| Warrants [Member]
Exercise price per share	18.75		18.75
Minimum [Member]
Anti-dilution provisions warrants exercise price			$ 6.00
Probability of exercise of additional warrants at exercise price one			60.00%
Probability of exercise of additional warrants at exercise price two			50.00%
Exercise price per share	5.63		$ 5.63		$ 2.76
Minimum [Member] \| Warrants [Member]
Exercise price per share	$ 2.76		$ 2.76
Equity Warrants [Member]
Warrants outstanding	3,230,000		3,230,000		4,100,000
Liability Warrant [Member]
Warrants outstanding	3,260,000		3,260,000		4,200,000
Fair value of embedded derivative	$ 29,000		$ 29,000		$ 123,000
Liability Warrants One [Member]
Weighted average anti-dilutive warrants					60,000
Liability Warrants Two [Member]
Weighted average anti-dilutive warrants	29,000		29,000			123,000

Derivative Instruments - Schedule of Warrants Activity (Details)

9 Months Ended

Jul. 31, 2015

$ / shares

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Number of Warrants, Outstanding, Beginning balance | shares

4,158,092

Number of Warrants, Issued | shares

2,361

Number of Warrants, Exercised | shares

(758,032)

^[1]

Number of Warrants, Expired | shares

(139,413)

Number of Warrants, Outstanding, Ending balance | shares

3,263,008

Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares

$ 5.42

Weighted-Average Exercise Price, Issued | $ / shares

7.20

Weighted-Average Exercise Price, Exercised | $ / shares

5.10

^[1]

Weighted-Average Exercise Price, Expired | $ / shares

10.47

Weighted-Average Exercise Price, Outstanding, Ending | $ / shares

$ 5.05

[1]	Includes the cashless exercise of 291,322 warrants that resulted in the issuance of 216,261 shares of common stock.

Derivative Instruments - Schedule of Warrants Activity (Details) (Parenthetical)	9 Months Ended
	Jul. 31, 2015 shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Cashless exercise of warrants	291,322
Warrants resulted number of issuance of common stock	216,261

Derivative Instruments - Schedule of Fair Value of Warrant Liability (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Stock Price	$ 16.66	$ 3.18
Minimum [Member]
Exercise Price	$ 5.63	$ 2.76
Expected term	92 days	4 days
Volatility	84.24%	55.41%
Risk Free Rate	0.08%	0.01%
Maximum [Member]
Exercise Price	$ 18.75	$ 21.25
Expected term	733 days	1006 days
Volatility	99.38%	129.38%
Risk Free Rate	0.67%	1.62%

Share Based Compensation (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	Mar. 31, 2014	Oct. 31, 2013	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Stock compensation expense			$ 60,795		$ 150,883
Share-based compensation, common stock, shares			3,130		2,346
Share-based compensation, shares on net basis after employee payroll taxes			14,435		12,528
Unrecognized compensation cost related to nonvested stock option awards			$ 9,055,000		$ 9,055,000
Recognized over a remaining average vesting period					1 year 4 months 2 days
Aggregate intrinsic value of outstanding options			7,661,000		$ 7,661,000
Compensation cost related to outstanding stock options			6,036,456	$ 1,739,037	$ 15,836,492	$ 4,599,259
Number of options, granted					1,618,995
Stock Options [Member]
Unrecognized compensation cost related to nonvested stock option awards			21,714,000		$ 21,714,000
Recognized over a remaining average vesting period						1 year 7 months 13 days
Aggregate intrinsic value of outstanding options			2,289,000		2,289,000
Compensation cost related to outstanding stock options			1,959,000	$ 212,000	$ 6,824,000	$ 729,000
Number of options, granted					1,618,995	36,000
Fair value of option granted					$ 28,318,000	$ 145,000
Number of shares exercised					137,667
Cash proceeds from stock option exercised					$ 58,400
Director [Member]
Stock compensation expense			$ 264,552		$ 967,631
Share-based compensation, common stock, shares			23,955		239,850
Share-based compensation, shares on net basis after employee payroll taxes					226,423
2013 Base Salary Stock [Member]
Issuance of common stock					34,752
Number of stock shares issued during period amount					$ 182,919
2014 Cash Bonus Equity [Member]
Issuance of common stock					57,990
Number of stock shares issued during period amount					$ 206,125
2014 Voluntary Request To Purchase Of Equity [Member]
Issuance of common stock					15,950
Number of stock shares issued during period amount					$ 68,750
Common Stock [Member]
Issuance of common stock	3,333	13,500
Number of stock shares issued during period amount	$ 10,000	$ 54,000
Promissory Note One [Member]
Issuance of common stock					21,091
Number of stock shares issued during period amount					$ 66,500
Daniel J. O' Connor [Member]
Issuance of common stock					146,616
Number of stock shares issued during period amount					$ 588,294
Sara M. Bonstein [Member] \| Stock Bonus Award [Member]
Stock compensation expense			$ 2,361,716		$ 3,633,886
Share-based compensation, common stock, shares			129,154		292,832
Share-based compensation, shares on net basis after employee payroll taxes			100,726		211,957
Percentage of bonus paid			75.00%		75.00%
Dr. Petit [Member] \| Stock Bonus Award [Member]
Share-based compensation, shares on net basis after employee payroll taxes					104,461
Percentage of bonus paid			100.00%		100.00%
Fair value of equity purchases value					$ 457,125
Number of shares for equity purchases					137,275
Non Executive Employees [Member] \| Stock Bonus Award [Member]
Share-based compensation, shares on net basis after employee payroll taxes					14,300
Fair value of equity purchases value					$ 67,671
Number of shares for equity purchases					20,322
Consultants [Member]
Stock issued during period for services			75,628		319,278
Stock issued during period value for services			$ 1,390,107		$ 3,768,014
2015 Plan [Member]
Common stock issued during period					3,600,000
Additional common stock issued during period					650,000

Share Based Compensation - Schedule of Allocation of Base Salary (Details) - USD ($)	9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Annual Amount to be Purchased	$ 15,836,492	$ 4,599,259
Cumulative Net Purchase	94,788,419	$ 14,820,105
Daniel J. O' Connor [Member]
Annual Amount to be Purchased	89,064
Cumulative Gross Purchase	$ 67,494
Cumulative shares Gross Purchase	6,664
Cumulative Net Purchase	$ 61,916
Cumulative shares Net Purchase	6,329
David J. Mauro [Member]
Annual Amount to be Purchased	$ 16,531
Cumulative Gross Purchase	$ 12,568
Cumulative shares Gross Purchase	1,257
Cumulative Net Purchase	$ 9,514
Cumulative shares Net Purchase	980
Gregory T. Mayes [Member]
Annual Amount to be Purchased	$ 23,477
Cumulative Gross Purchase	$ 17,427
Cumulative shares Gross Purchase	1,679
Cumulative Net Purchase	$ 14,082
Cumulative shares Net Purchase	1,387
Robert G. Petit [Member]
Annual Amount to be Purchased	$ 25,225
Cumulative Gross Purchase	$ 19,335
Cumulative shares Gross Purchase	1,942
Cumulative Net Purchase	$ 14,499
Cumulative shares Net Purchase	1,507
Sara M. Bonstein [Member]
Annual Amount to be Purchased	$ 19,734
Cumulative Gross Purchase	$ 14,665
Cumulative shares Gross Purchase	1,417
Cumulative Net Purchase	$ 11,695
Cumulative shares Net Purchase	1,137

Share Based Compensation - Summary of RSU Activity and Related Information (Details)

9 Months Ended

Jul. 31, 2015

$ / shares

Beginning balance | shares

467,968

Number of RSUs Granted | shares

1,618,995

Number of RSUs Vested | shares

(137,667)

^[1]

Number of RSUs Cancelled | shares

(16,142)

Ending Balance | shares

1,933,154

Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares

$ 15.51

Weighted-Average Exercise Price, Granted | $ / shares

13.29

Weighted-Average Exercise Price, Exercised | $ / shares

12.29

^[1]

Weighted-Average Exercise Price, Expired | $ / shares

36.42

Weighted-Average Exercise Price, Outstanding, Ending | $ / shares

$ 13.70

Restricted Stock Units (RSUs) [Member]

Beginning balance | shares

791,879

Number of RSUs Granted | shares

641,452

Number of RSUs Vested | shares

(326,747)

Number of RSUs Cancelled | shares

(3,333)

Ending Balance | shares

10,657,251

Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares

$ 3.81

Weighted-Average Exercise Price, Granted | $ / shares

16.00

Weighted-Average Exercise Price, Exercised | $ / shares

8.60

Weighted-Average Exercise Price, Expired | $ / shares

11.76

Weighted-Average Exercise Price, Outstanding, Ending | $ / shares

$ 9.48

[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Stock Options - Summary of Changes in Stock Option Plan (Details)

9 Months Ended

Jul. 31, 2015

$ / shares

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Beginning balance | shares

467,968

Number of Options, Granted | shares

1,618,995

Number of Options, Exercised | shares

(137,667)

^[1]

Number of Options, Expired | shares

(16,142)

Ending Balance | shares

1,933,154

Number of Options, Vested and Exercisable | shares

712,957

Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares

$ 15.51

Weighted-Average Exercise Price, Granted | $ / shares

13.29

Weighted-Average Exercise Price, Exercised | $ / shares

12.29

^[1]

Weighted-Average Exercise Price, Expired | $ / shares

36.42

Weighted-Average Exercise Price, Outstanding, Ending | $ / shares

13.70

Weighted-Average Exercise Price, Vested and Exercisable | $ / shares

$ 14.18

[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Stock Options - Summary of Changes in Stock Option Plan (Details) (Parenthetical)	9 Months Ended
	Jul. 31, 2015 shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Cashless exercise of stock options	117,667
Stock option resulted number of issuance of common stock	45,167

Share Based Compensation - Summary of BSM (Details)	9 Months Ended
Share Based Compensation - Summary of BSM (Details)	Jul. 31, 2015	Jul. 31, 2014
Expected Term		5 years
Expected Volatility, Minimum	108.72%	151.38%
Expected Volatility, Maximum	154.54%	171.12%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	1.41%	1.39%
Risk Free Interest Rate, Maximum	2.27%	1.72%
Minimum [Member]
Expected Term	5 years
Maximum [Member]
Expected Term	10 years

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Share-based compensation expense	$ 6,036,456	$ 1,739,037	$ 15,836,492	$ 4,599,259
Research and Development Expenses [Member]
Share-based compensation expense	2,499,097	303,516	4,896,922	888,457
General and Administrative Expenses [Member]
Share-based compensation expense	$ 3,537,359	$ 1,435,521	$ 10,939,570	$ 3,710,802

Commitments and Contingencies (Details Narrative)		1 Months Ended	9 Months Ended
Commitments and Contingencies (Details Narrative)	Oct. 01, 2014 USD ($)	May 31, 2015 USD ($) ft²	Jul. 31, 2015 $ / shares shares
Security deposit		$ 82,426
Area of office space \| ft²		20,000
Lease expire		Nov. 30, 2022
Lease term		7 years
Base annual rent		$ 442,000
Operating leases annual rent, description		The lease requires base annual rent of approximately $442,000 with annual increases in increments between 2% and 4% throughout the remainder of the lease.
Leases renewal term		5 years
Knoll Capital Management [Member] \| August 21, 2015 [Member]
Number of shares complaint alleges of common stock \| shares			1,666,666.67
Common stock price per share \| $ / shares			$ 3.00
Numoda Corporation [Member]
Seeking declaratory judgment amount	$ 68,884

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Jul. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2015 (Remaining)	$ 60,000
2016	424,927
2017	450,451
2018	468,947
2019	488,153
Thereafter	$ 1,625,308

Shareholders' Equity (Details Narrative) - USD ($)						1 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Aug. 28, 2015	May 05, 2015	Feb. 18, 2015	Dec. 22, 2014	Dec. 19, 2014	May 31, 2015
Number of shares issued during period for registered direct offering			3,068,095		3,940,801
Proceeds from registered direct offering, net of offering expenses				$ 15,800,000
Common Stock at public offering		2,800,000
Common stock at public offering price per share		$ 19.00
Gross proceeds from public offering		$ 61,200,000
Proceeds from public offering	$ 25,000,000		$ 22,300,000			$ 56,700,000
Over-Allotment Option [Member]
Common Stock at public offering		420,000
Common stock at public offering price per share		$ 19.00
Gross proceeds from public offering		$ 56,700,000
Registered Direct Offering [Member]
Common stock price per share			$ 7.50		$ 4.25
Proceeds from received from offering			$ 23,000,000		$ 16,700,000
Proceeds from registered direct offering, net of offering expenses			$ 22,300,000		$ 15,800,000

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Jul. 31, 2015	Oct. 31, 2014
Common stock warrant liability, warrants exercisable	$ 295,183	$ 32,091
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 295,183	$ 32,091

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2015	Oct. 31, 2014
Exercise price per share	$ 5.05	$ 5.42
Warrants exercisable period	May 2015 through August 2017	November 2014 through August 2017
Minimum [Member]
Exercise price per share	$ 5.63	$ 2.76
Maximum [Member]
Exercise price per share	$ 18.75	$ 21.25

Fair Value - Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation (Details)	9 Months Ended
	Jul. 31, 2015 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance	$ 32,091
Issuance of additional warrants due to anti-dilution provisions	8,169
Change in fair value	254,923
Ending Balance	$ 295,183

Subsequent Events (Details Narrative) - USD ($)							9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Sep. 08, 2015	Aug. 31, 2015	Aug. 18, 2015	Aug. 17, 2015	Aug. 13, 2015	Aug. 10, 2015	Jul. 31, 2015	Jul. 31, 2014
Net proceeds of common stock							$ 94,788,419	$ 14,820,105
Subsequent Event [Member]
Options to purchase of common stock					50,000
Options to purchase of common stock exercise price					$ 17.22
Shares issued to employee			2,379	1,250
Net proceeds of common stock							$ 25,000,000
Number of shares issued during period to employees	8,750	1,020
Subsequent Event [Member] \| Sectoral Asset Management [Member]
Number of shares issued during period							1,437,815
Common stock price per share							$ 13.91
Subsequent Event [Member] \| Restricted Stock Units (RSUs) [Member]
Shares available for grant					15,240
Subsequent Event [Member] \| Knight [Member]
Number of shares issued during period							359,454
Common stock price per share							$ 13.91
Subsequent Event [Member] \| August 13, 2016 [Member]
Options expiration period					10 years
Subsequent Event [Member] \| October 31, 2015 [Member] \| Restricted Stock Units (RSUs) [Member]
Shares available for grant					2,740
Subsequent Event [Member] \| October 31, 2016 [Member] \| Restricted Stock Units (RSUs) [Member]
Shares available for grant					12,500
Percentage of Shares available for grant					100.00%
Subsequent Event [Member] \| Governor Ridge [Member]
Common stock issued for services					636
Common stock issued for services, value					$ 10,952
Subsequent Event [Member] \| Accredited Investor [Member]
Common stock issued for services						58,126
Common stock issued for services, value						$ 921,297